Weekly Analysts’ Ratings Changes for Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (NASDAQ: IONS) recently received a number of ratings updates from brokerages and research firms:

• 8/3/2026 – Ionis Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $72.00 to $76.00. They now have an “overweight” rating on the stock.
• 8/1/2026 – Ionis Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/30/2026 – Ionis Pharmaceuticals had its price target lowered by Wells Fargo & Company from $100.00 to $95.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – Ionis Pharmaceuticals had its price target lowered by HC Wainwright from $125.00 to $115.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Ionis Pharmaceuticals had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $69.00 price target on the stock.
• 7/23/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
• 7/21/2026 – Ionis Pharmaceuticals had its price target lowered by Guggenheim from $106.00 to $89.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Ionis Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Ionis Pharmaceuticals had its “peer perform” rating reaffirmed by Wolfe Research.
• 7/13/2026 – Ionis Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $100.00 to $85.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by Citigroup Inc. from $115.00 to $100.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by Barclays PLC from $115.00 to $90.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by HC Wainwright from $130.00 to $125.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by Morgan Stanley from $130.00 to $110.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – Ionis Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $110.00 to $95.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Ionis Pharmaceuticals had its price target lowered by Jefferies Financial Group Inc. from $113.00 to $90.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Ionis Pharmaceuticals had its price target lowered by Jefferies Financial Group Inc. from $113.00 to $90.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Ionis Pharmaceuticals was given a new $87.00 price target by Raymond James Financial, Inc..
• 7/9/2026 – Ionis Pharmaceuticals had its price target lowered by Needham & Company LLC from $105.00 to $86.00. They now have a “buy” rating on the stock.
• 6/25/2026 – Ionis Pharmaceuticals had its price target raised by HC Wainwright from $125.00 to $130.00. They now have a “buy” rating on the stock.
• 6/25/2026 – Ionis Pharmaceuticals had its price target raised by Leerink Partners from $122.00 to $129.00. They now have an “outperform” rating on the stock.
• 6/24/2026 – Ionis Pharmaceuticals had its price target raised by The Goldman Sachs Group, Inc. from $74.00 to $75.00. They now have a “neutral” rating on the stock.

Insider Activity

In other news, CEO Brett P. Monia sold 50,000 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $80.59, for a total value of $4,029,500.00. Following the completion of the sale, the chief executive officer owned 245,571 shares in the company, valued at $19,790,566.89. This represents a 16.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Eugene Schneider sold 26,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $81.05, for a total value of $2,107,300.00. Following the transaction, the executive vice president directly owned 77,114 shares of the company’s stock, valued at $6,250,089.70. This represents a 25.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 233,163 shares of company stock worth $18,316,551 in the last quarter. 1.81% of the stock is currently owned by corporate insiders.

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.